Sally Arai, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Arai’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G87299 · Current
Licensed to practise in California · since 2004 · expires 2027-09-30 · Dartmouth Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$34,056
Medicare paid this office $34,056 for 73 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $16,258 | $70 |
| Long return visit (40+ min) | 19 | $5,752 | $128 |
| Return visit (30+ min) | 32 | $5,364 | $85 |
Who their Medicare patients are
73 Original Medicare patients in 2024. Average age 68 · Women 52% · Also on Medicaid 32% · Health risk score 3.36. Sicker patients than 9 in 10 peers; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 62% · Chronic kidney disease 26% · Depression 23% · Coronary heart disease 21% · Diabetes 19% · Heart failure 18% · Cancer 18% · Atrial fibrillation 16% · Dementia 16%.
The office billed $122,973, Medicare allowed $43,327 and paid $34,056; for 397 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 73 | 397 | 68 | 3.36 | $122,973 | $34,056 |
| 2023 | 82 | 416 | 65 | 3.79 | $151,327 | $38,596 |
| 2022 | 84 | 380 | 68 | 2.58 | $165,118 | $39,627 |
| 2021 | 77 | 420 | 67 | 2.91 | $170,818 | $41,813 |
| 2020 | 92 | 382 | 67 | 4.05 | $168,318 | $35,885 |
| 2019 | 105 | 377 | 66 | 3.53 | $197,946 | $36,349 |
| 2018 | 87 | 400 | 64 | 4.06 | $178,268 | $37,238 |
| 2017 | 100 | 537 | 64 | 3.32 | $210,663 | $51,126 |
| 2016 | 77 | 271 | 62 | 3.16 | $104,863 | $24,566 |
| 2015 | 70 | 395 | 63 | 3.52 | $165,370 | $35,976 |
| 2014 | 82 | 462 | 63 | 2.89 | $190,442 | $42,218 |
| 2013 | 81 | 470 | 62 | 3.01 | $199,146 | $44,712 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $12,622 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $10,971 | $105 |
| Long return visit (40+ min) | 23 | $5,512 | $128 |
| Return visit (30+ min) | 24 | $3,706 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,913 | $120 |
| Hospital discharge day management, 30 minutes or less | 12 | $911 | $76 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $17,780 | $94 |
| Long return visit (40+ min) | 34 | $8,116 | $131 |
| Return visit (30+ min) | 31 | $6,323 | $90 |
2021: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $22,014 | $95 |
| Return visit (30+ min) | 33 | $6,720 | $88 |
| Long return visit (40+ min) | 22 | $4,468 | $128 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,223 | $68 |
2020: 4 services
| Long return visit (40+ min) | 49 | $12,731 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $11,506 | $95 |
| Return visit (30+ min) | 36 | $6,205 | $72 |
| Hospital discharge day management, 30 minutes or less | 13 | $849 | $65 |
2019: 3 services
| Long return visit (40+ min) | 65 | $13,758 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $11,037 | $94 |
| Return visit (30+ min) | 40 | $5,141 | $69 |
2018: 4 services
| Long return visit (40+ min) | 57 | $20,494 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $9,852 | $91 |
| Return visit (30+ min) | 31 | $2,614 | $65 |
| Hospital discharge day management, 30 minutes or less | 11 | $802 | $67 |
2017: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $22,915 | $93 |
| Long return visit (40+ min) | 45 | $16,130 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,538 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,953 | $122 |
| Return visit (30+ min) | 23 | $1,811 | $67 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,789 | $66 |
2016: 2 services
| Long return visit (40+ min) | 53 | $18,223 | $94 |
| Return visit (30+ min) | 19 | $1,922 | $62 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $14,809 | $92 |
| Long return visit (40+ min) | 44 | $12,758 | $95 |
| Return visit (30+ min) | 18 | $2,503 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,815 | $113 |
| Hospital discharge day management, 30 minutes or less | 12 | $787 | $61 |
2014: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $17,745 | $92 |
| Long return visit (40+ min) | 43 | $12,329 | $96 |
| Return visit (30+ min) | 29 | $5,585 | $70 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,048 | $65 |
2013: 4 services
| Long return visit (40+ min) | 61 | $25,636 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $11,194 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $3,325 | $175 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,149 | $64 |
Medicaid work
$7,475 in 2024
Medicaid paid $7,475 for 92 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 92 | $7,475 |
| 2024 | 92 | 1 | 12 | $7,475 |
| 2021 | 18 | 1 | 17 | $1,260 |
| 2019 | 40 | 1 | 16 | $2,800 |
| 2018 | 49 | 1 | 16 | $3,313 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 18 | $1,260 |
2019
| Long return visit (40+ min) | 40 | $2,800 |
2018
| Long return visit (40+ min) | 49 | $3,313 |
Drugs they prescribed that Part D paid
$1,413,339
Pharmacies billed $1,413,339 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 532) in 2024. At or below the middle of the specialty; the typical hematology clinician is at 4%.
420 generic and 112 brand-name prescriptions · $1,413,339 in drug cost · 73 antibiotic prescriptions to 28 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 31 | $557,385 | $17,980 |
| Rezurock | 25 | $528,469 | $21,139 |
| Cresemba | 25 | $168,870 | $6,755 |
| Posaconazole | 26 | $45,945 | $1,767 |
| Atovaquone | 38 | $22,656 | $596 |
See all 12 drugs
| Jakafi | 31 | $557,385 | $17,980 |
| Rezurock | 25 | $528,469 | $21,139 |
| Cresemba | 25 | $168,870 | $6,755 |
| Posaconazole | 26 | $45,945 | $1,767 |
| Atovaquone | 38 | $22,656 | $596 |
| Eliquis | 13 | $8,004 | $616 |
| Entecavir | 13 | $3,851 | $296 |
| Acyclovir | 82 | $2,056 | $25 |
| Prednisone | 32 | $364 | $11 |
| Sulfamethoxazole-Trimethoprim | 41 | $349 | $9 |
| Gabapentin | 13 | $230 | $18 |
| Amlodipine Besylate | 14 | $85 | $6 |
Year by year
| 2024 | 532 | 53 | 0% (0) | 21% | $1,413,339 |
| 2023 | 433 | 48 | 0% (0) | None | $894,190 |
| 2022 | 567 | 48 | None | None | $979,371 |
| 2021 | 628 | 41 | None | None | $882,878 |
| 2020 | 672 | 37 | 2% (11) | None | $705,755 |
| 2019 | 707 | 50 | None | 14% | $612,352 |
| 2018 | 682 | 47 | None | 9% | $479,069 |
| 2017 | 815 | 54 | 4% (34) | 10% | $348,412 |
| 2016 | 447 | 42 | None | None | $117,538 |
| 2015 | 473 | 51 | None | None | $117,118 |
| 2014 | 483 | 47 | 6% (27) | 14% | $122,917 |
| 2013 | 202 | 42 | 7% (14) | 11% | $55,659 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Jakafi | 20 | $412,185 | $20,609 |
| Rezurock | 18 | $332,831 | $18,491 |
| Posaconazole | 19 | $25,731 | $1,354 |
| Atovaquone | 29 | $19,616 | $676 |
| Eliquis | 11 | $6,746 | $613 |
| Acyclovir | 67 | $2,209 | $33 |
| Sulfamethoxazole-Trimethoprim | 48 | $634 | $13 |
| Prednisone | 32 | $367 | $11 |
| Mirtazapine | 11 | $359 | $33 |
| Gabapentin | 11 | $210 | $19 |
| Risperidone | 12 | $25 | $2 |
2022: 10 drugs
| Jakafi | 30 | $589,398 | $19,647 |
| Rezurock | 14 | $237,740 | $16,981 |
| Rapamune | 11 | $20,465 | $1,860 |
| Atovaquone | 20 | $16,435 | $822 |
| Acyclovir | 115 | $3,493 | $30 |
| Dexamethasone | 14 | $790 | $56 |
| Prednisone | 39 | $454 | $12 |
| Sulfamethoxazole-Trimethoprim | 40 | $294 | $7 |
| Gabapentin | 12 | $292 | $24 |
| Amlodipine Besylate | 16 | $24 | $2 |
2021: 18 drugs
| Jakafi | 41 | $554,521 | $13,525 |
| Cresemba | 19 | $107,520 | $5,659 |
| Posaconazole | 11 | $31,529 | $2,866 |
| Zarxio | 15 | $27,872 | $1,858 |
| Rapamune | 12 | $23,072 | $1,923 |
| Atovaquone | 24 | $19,562 | $815 |
| Acyclovir | 100 | $2,587 | $26 |
| Ursodiol | 12 | $1,372 | $114 |
| Entecavir | 15 | $1,352 | $90 |
| Prednisone | 35 | $551 | $16 |
| Sulfamethoxazole-Trimethoprim | 49 | $466 | $10 |
| Ondansetron | 18 | $360 | $20 |
| Rizatriptan | 12 | $212 | $18 |
| Gabapentin | 14 | $176 | $13 |
| Amlodipine Besylate | 12 | $146 | $12 |
| Levofloxacin | 11 | $120 | $11 |
| Penicillin V | 12 | $77 | $6 |
| Lorazepam | 12 | $74 | $6 |
2020: 22 drugs
| Iclusig | 11 | $192,381 | $17,489 |
| Jakafi | 12 | $183,192 | $15,266 |
| Posaconazole | 16 | $81,328 | $5,083 |
| Noxafil | 11 | $71,649 | $6,514 |
| Atovaquone | 23 | $22,375 | $973 |
| Rapamune | 12 | $21,361 | $1,780 |
| Sirolimus | 14 | $5,073 | $362 |
| Tacrolimus | 18 | $2,976 | $165 |
| Acyclovir | 99 | $2,514 | $25 |
| Valacyclovir | 13 | $1,170 | $90 |
| Prednisone | 60 | $738 | $12 |
| Dapsone | 11 | $559 | $51 |
| Sulfamethoxazole-Trimethoprim | 66 | $552 | $8 |
| Dexamethasone | 11 | $466 | $42 |
| Prochlorperazine Maleate | 14 | $383 | $27 |
| Pantoprazole | 22 | $315 | $14 |
| Famotidine | 15 | $132 | $9 |
| Sertraline | 17 | $127 | $7 |
| Trazodone | 16 | $103 | $6 |
| Penicillin V | 11 | $98 | $9 |
| Amlodipine Besylate | 14 | $44 | $3 |
| Alprazolam | 11 | $42 | $4 |
2019: 20 drugs
| Jakafi | 11 | $174,681 | $15,880 |
| Noxafil | 31 | $124,885 | $4,029 |
| Atovaquone | 17 | $13,882 | $817 |
| Acyclovir | 122 | $2,751 | $23 |
| Entecavir | 14 | $1,241 | $89 |
| Tacrolimus | 14 | $1,217 | $87 |
| Sulfamethoxazole-Trimethoprim | 62 | $1,177 | $19 |
| Dexamethasone | 25 | $994 | $40 |
| Mycophenolate Mofetil | 14 | $956 | $68 |
| Prednisone | 73 | $788 | $11 |
| Famciclovir | 11 | $751 | $68 |
| Clotrimazole | 11 | $653 | $59 |
| Pantoprazole | 13 | $500 | $38 |
| Trazodone | 11 | $199 | $18 |
| Famotidine | 26 | $197 | $8 |
| Penicillin V | 11 | $177 | $16 |
| Amoxicillin | 19 | $161 | $8 |
| Amlodipine Besylate | 13 | $160 | $12 |
| Alendronate | 11 | $120 | $11 |
| Omeprazole | 12 | $99 | $8 |
2018: 17 drugs
| Iclusig | 12 | $214,655 | $17,888 |
| Noxafil | 15 | $92,501 | $6,167 |
| Voriconazole | 15 | $17,800 | $1,187 |
| Atovaquone | 15 | $10,874 | $725 |
| Acyclovir | 141 | $4,563 | $32 |
| Entecavir | 14 | $2,220 | $159 |
| Tacrolimus | 14 | $1,759 | $126 |
| Pantoprazole | 27 | $551 | $20 |
| Sulfamethoxazole-Trimethoprim | 65 | $533 | $8 |
| Prednisone | 39 | $502 | $13 |
| Dexamethasone | 13 | $395 | $30 |
| Ondansetron | 21 | $249 | $12 |
| Famotidine | 36 | $220 | $6 |
| Amoxicillin | 11 | $158 | $14 |
| Azithromycin | 13 | $137 | $11 |
| Prochlorperazine Maleate | 12 | $82 | $7 |
| Omeprazole | 12 | $67 | $6 |
2017: 18 drugs
| Noxafil | 25 | $139,704 | $5,588 |
| Acyclovir | 167 | $3,405 | $20 |
| Tacrolimus | 35 | $1,939 | $55 |
| Valacyclovir | 12 | $1,037 | $86 |
| Dapsone | 12 | $943 | $79 |
| Sulfamethoxazole-Trimethoprim | 55 | $767 | $14 |
| Morphine Sulfate Er | 14 | $522 | $37 |
| Prednisone | 37 | $469 | $13 |
| Pantoprazole | 45 | $440 | $10 |
| Ondansetron | 21 | $424 | $20 |
| Tamsulosin | 12 | $217 | $18 |
| Gabapentin | 16 | $202 | $13 |
| Famotidine | 33 | $194 | $6 |
| Levothyroxine | 12 | $158 | $13 |
| Bupropion Hcl Sr | 12 | $80 | $7 |
| Amlodipine Besylate | 22 | $66 | $3 |
| Pravastatin | 13 | $57 | $4 |
| Lorazepam | 11 | $50 | $5 |
2016: 10 drugs
| Cresemba | 15 | $45,835 | $3,056 |
| Acyclovir | 74 | $1,086 | $15 |
| Tacrolimus | 11 | $701 | $64 |
| Prednisone | 26 | $445 | $17 |
| Sulfamethoxazole-Trimethoprim | 38 | $317 | $8 |
| Levothyroxine | 14 | $182 | $13 |
| Famotidine | 24 | $134 | $6 |
| Azithromycin | 13 | $70 | $5 |
| Amlodipine Besylate | 23 | $38 | $2 |
| Omeprazole | 13 | $31 | $2 |
2015: 12 drugs
| Noxafil | 12 | $33,309 | $2,776 |
| Fluconazole | 14 | $1,832 | $131 |
| Tacrolimus | 19 | $1,636 | $86 |
| Acyclovir | 83 | $1,488 | $18 |
| Mycophenolate Mofetil | 13 | $818 | $63 |
| Sulfamethoxazole-Trimethoprim | 48 | $486 | $10 |
| Prednisone | 25 | $444 | $18 |
| Azithromycin | 15 | $434 | $29 |
| Famotidine | 34 | $202 | $6 |
| Levothyroxine | 11 | $174 | $16 |
| Omeprazole | 17 | $67 | $4 |
| Amlodipine Besylate | 12 | $40 | $3 |
2014: 14 drugs
| Acyclovir | 85 | $2,004 | $24 |
| Fluconazole | 14 | $1,385 | $99 |
| Mycophenolate Mofetil | 17 | $1,139 | $67 |
| Azithromycin | 13 | $865 | $67 |
| Dapsone | 16 | $551 | $34 |
| Pantoprazole | 18 | $342 | $19 |
| Sulfamethoxazole-Trimethoprim | 34 | $320 | $9 |
| Ciprofloxacin | 17 | $312 | $18 |
| Hydrocodone-Acetaminophen | 12 | $298 | $25 |
| Famotidine | 26 | $218 | $8 |
| Prednisone | 11 | $180 | $16 |
| Lorazepam | 18 | $116 | $6 |
| Ranitidine | 11 | $100 | $9 |
| Omeprazole | 14 | $88 | $6 |
2013: 1 drug
| Acyclovir | 39 | $1,206 | $31 |
Money from drug and device companies
$1,011 in 2025
| 2025 | 2 | 4 | None | $1,011 |
| 2024 | 2 | 8 | None | $1,863 |
| 2023 | 2 | 3 | None | $674 |
| 2022 | 1 | 1 | $2,280 | $2,280 |
| 2021 | 1 | 1 | None | $25 |
| 2020 | 1 | 1 | $3,120 | $3,120 |
| 2019 | 1 | 1 | None | $56 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sanofi-Aventis U.S. | None | $506 | 2 payments
|
| Genzyme | None | $505 | 2 payments
|
See all 4 published payments
| Genzyme | Meals · 2025-10-18 | None | $230 |
| Genzyme | Travel · 2025-10-18 | None | $275 |
| Sanofi-Aventis U.S. | Meals · 2025-01-30 | None | $213 |
| Sanofi-Aventis U.S. | Travel · 2025-01-29 | None | $293 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,863
| Incyte | None | $1,637 | 6 payments
|
| Novartis Pharmaceuticals | Kymriah | $226 | 2 payments
|
2023: $674
| Sanofi-Aventis U.S. | Rezurock | $484 | 2 payments
|
| National Marrow Donor Program | None | $189 | 1 payment
|
2022: $2,280
| Sanofi-Aventis U.S. | Rezurock | $2,280 | 1 payment
|
2021: $25
| CSL Behring | Hizentra | $25 | 1 payment
|
2020: $3,120
| Kadmon Pharmaceuticals | None | $3,120 | 1 payment
|
2019: $56
| Kadmon Pharmaceuticals | None | $56 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added To Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-Versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant · 2019 | Their institution | $758,413 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label Study of Defibrotide for the Prevention of Acute Graft-Versus-Host-Disease (Agvhd) · 2019 | Their institution | $181,449 |
| Syndax Pharmaceuticals, Inc. · Agave-201, A Phase 2, Open-Label, Randomized, Multicenter Study To Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent Or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy · 2025 | Their institution | $139,438 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2022 | Their institution | $137,474 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2023 | Their institution | $102,147 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant (Bmt Ctn 1705) · 2024 | Their institution | $100,558 |
| National Marrow Donor Program · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant (Bmt Ctn 1705) · 2024 | Their institution | $100,528 |
| National Marrow Donor Program · A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As Gvhd Prophylaxis in Adult Patients With Hematologic Malignancies Receiving Hla-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation · 2025 | Their institution | $87,500 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2021 | Their institution | $50,880 |
| Incyte Corporation · A Study To Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease · 2025 | Their institution | $50,435 |
| National Marrow Donor Program · A Multi-Center, Phase II Trial of Hla-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies · 2024 | Their institution | $47,000 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label Study of Defibrotide for the Prevention of Acute Graft-Versus-Host-Disease (Agvhd) · 2020 | Their institution | $46,050 |
| National Marrow Donor Program · A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As Gvhd Prophylaxis in Adult Patients With Hematologic Malignancies Receiving Hla-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation · 2024 | Their institution | $42,000 |
| SANOFI US SERVICES INC. · Extended Treatment and Follow-Up of Subjects Treated With Belumosudil in Study Kd025-208 Or Study Kd025-213 · 2022 | Their institution | $34,303 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease (Cgvhd) After at Least 2 Prior Lines of Systemic Therapy · 2022 | Their institution | $34,292 |
| National Marrow Donor Program · A Multi-Center, Phase II Trial of Hla-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies · 2025 | Their institution | $32,500 |
| National Marrow Donor Program · Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation · 2022 | Their institution | $25,862 |
| National Marrow Donor Program · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2023 | Their institution | $25,700 |
| National Marrow Donor Program · A Multi-Center, Phase II Trial of Hla-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies · 2023 | Their institution | $25,000 |
| JAZZ PHARMACEUTICALS INC. · An Open-Label Study of Defibrotide for the Prevention of Acute Graft-Versus-Host-Disease (Agvhd) · 2021 | Their institution | $18,692 |
| National Marrow Donor Program · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2023 | Their institution | $17,000 |
| National Marrow Donor Program · A Phase II Study Evaluating the Safety and Efficacy of Mgta-145 in Combination With Plerixafor for the Mobilization and Transplantation of Hla-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies · 2022 | Their institution | $16,100 |
| National Marrow Donor Program · A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially Hla-Mismatched, Or Matched Unrelated Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia · 2025 | Their institution | $15,929 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease (Cgvhd) After at Least 2 Prior Lines of Systemic Therapy (the Rockstar Study) · 2021 | Their institution | $15,568 |
| VectivBio AG · Graft Vs Host Disease · 2024 | Their institution | $14,290 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2024 | Their institution | $7,453 |
| SANOFI US SERVICES INC. · Extended Treatment and Follow-Up of Subjects Treated With Belumosudil in Study Kd025-208 Or Study Kd025-213 · 2023 | Their institution | $6,405 |
| Kite Pharma, Inc. · A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab Or Lenalidomide in Subjects With Refractory Large B-Cell Lymphoma (Zuma-14) · 2022 | Their institution | $5,784 |
| Seagen Inc. · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Sgn-35 and Best Supportive Care (Bsc) Versus Placebo and Bsc in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant · 2020 | Their institution | $5,081 |
| SANOFI US SERVICES INC. · A Phase 2, Randomized, Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease (Cgvhd) After at Least 2 Prior Lines of Systemic Therapy · 2023 | Their institution | $3,258 |
| Kadmon Corporation LLC · A Phase 2 Randomized Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease Cgvhd After at Least 2 Prior Lines of Systemic Therapy · 2019 | Their institution | $2,913 |
| National Marrow Donor Program · Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation · 2023 | Their institution | $1,542 |
| National Marrow Donor Program · Facilitating Activation of Study Trials (Fast) · 2025 | Their institution | $1,000 |
| Adaptive Biotechnologies Corporation · Clonoseq · 2020 | Their institution | $900 |
| Kadmon Corporation LLC · A Phase 2, Randomized, Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease (Cgvhd) After at Least 2 Prior Lines of Systemic Therapy · 2020 | Their institution | $672 |
| Kadmon Corporation LLC · A Phase 2 Randomized Multicenter Study To Evaluate the Efficacy and Safety of Kd025 in Subjects With Chronic Graft Versus Host Disease Cgvhd After at Least 2 Prior Lines of Systemic Therapy · 2021 | Their institution | $432 |
| Seattle Genetics, Inc. · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Sgn-35 and Best Supportive Care Bsc Versus Placebo and Bsc in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant · 2019 | Their institution | $338 |
| Incyte Corporation · Agave-201, A Phase 2, Open-Label, Randomized, Multicenter Study To Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent Or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy · 2023 | Their institution | $236 |
| National Marrow Donor Program · Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (Bmt Ctn 1702) · 2024 | Their institution | $29 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1881739530
- Licence
- CA G87299California G87299: Current · expires 2027-09-30
- Trained
- Geisel School of Medicine at Dartmouth, 1991
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-20
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.